. Neuropathic pain is associated with increased drug prescriptions and visits to health care providers 3, 4 . Patients typically experience a distinct set of symptoms, such as burning and electricallike sensations, and pain resulting from nonpainful stimulations (such as light touching); the symptoms persist and have a tendency to become chronic and respond less to pain medica tions. Sleep disturbances, anxiety and depression are frequent and severe in patients with neuropathic pain, and quality of life is more impaired in patients with chronic neuropathic pain than in those with chronic non neuropathic pain that does not come from damaged or irritated nerves 3, 5 . Despite the increases of placebo responses 6,7 that result in the failure of multiple new drugs in clin ical trials, recent progress in our understanding of the pathophysiology of neuropathic pain provides optimism for the development of new diagnostic procedures and personalized interventions. This Primer presents the current descriptions of the presentation, causes, diag nosis and treatment of neuropathic pain, with a focus on peripheral neuropathic pain given that our knowledge is greater than that of central neuropathic pain.
Epidemiology
The estimation of the incidence and prevalence of neuro pathic pain has been difficult because of the lack of simple diagnostic criteria for large epidemiological surveys in the general population. Thus, the prevalence of neuro pathic pain in the chronic pain population has mainly been estimated on the basis of studies 8 conducted by specialized centres with a focus on specific conditions, such as postherpetic neuralgia 9, 10 , painful diabetic poly neuropathy 1, [11] [12] [13] , postsurgery neuropathic pain 14 , multiple sclerosis 15, 16 , spinal cord injury 17 , stroke 18 and cancer 19, 20 . The recent development of simple screening tools in the form of questionnaires 21 has helped conduct several large epidemiological surveys in different countries (the United Kingdom, the United States, France and Brazil) and provided valuable new information on the general prevalence of neuropathic pain 4 . In using screening tools, such as the Douleur Neuropathique 4 questions (DN4) 22 or the Leeds Assessment of Neuropathic Symptoms and Signs (LANSS) pain scale 23 (BOX 2), the prevalence of chronic pain with neuropathic characteristics has been estimated to be in the range of 7-10% 8, 24 . Chronic neuropathic pain is more frequent in women (8% versus 5.7% in men) and in patients >50 years of age (8.9% versus 5.6% in those <49 years of age), and most commonly affects the lower back and lower limbs, neck and upper limbs 24 . Lumbar and cervical painful radiculo pathies are probably the most frequent cause of chronic neuropathic pain. Consistent with these data, a survey of >12,000 patients with chronic pain with both nociceptive and neuropathic pain types, referred to pain specialists in Germany, revealed that 40% of all patients experience at least some characteristics of neuropathic pain (such as burning sensations, numb ness and tingling); patients with chronic back pain and radiculopathy were particularly affected 25 .
Mechanisms/pathophysiology
Research in the pain field has focused on understand ing the plastic changes in the nervous system after nerve injury, identifying novel therapeutic targets and in facili tating the transfer of knowledge from animal models to clinical practice. We describe briefly the multiple causes of neuropathic pain and present an overview of animal and human findings that have provided insights on the pathophysiology of neuropathic pain.
Causes and distributions
Central neuropathic pain is due to a lesion or disease of the spinal cord and/or brain. Cerebrovascular disease affecting the central somatosensory pathways (post stroke pain) and neurodegenerative diseases (notably Parkinson disease) are brain disorders that often cause central neuro pathic pain 26 . Spinal cord lesions or dis eases that cause neuropathic pain include spinal cord injury, syringo myelia and demyelinating diseases, such as multi ple sclerosis, transverse myelitis and neuro myelitis optica 27 . By contrast, the pathology of the peripheral disorders that cause neuropathic pain predominantly involves the small unmyelinated C fibres and the myelin ated A fibres, namely, the Aβ and Aδ fibres 5 . Peripheral neuropathic pain will probably become more common because of the ageing global population, increased inci dence of diabetes mellitus and the increasing rates of cancer and the consequence of chemotherapy, which affect all sensory fibres (Aβ, Aδ and C fibres). Peripheral neuropathic pain dis orders can be subdivided into those that have a general ized (usually symmetrical) distrib ution and those that have a focal distribution (FIG. 2) . The most clinically important painful generalized peripheral neuropathies include those associated with diabetes mellitus
, prediabetes and other meta bolic dys functions, infectious diseases (mainly HIV infection 28 and leprosy 29 ), chemotherapy, immune (for example, Guillain-Barré syndrome) and inflammatory dis orders, inherited neuropathies and channelopathies (such as inherited erythromelalgia, a disorder in which blood vessels are episodically blocked then become hyperaemic and inflamed).
The topography of the pain in these disorders typi cally encompasses the distal extremities, often called a 'glove and stocking' distribution because the feet, calves, hands and forearms are most prominently affected. This distribution pattern is characteristic of dyingback, lengthdependent, distal peripheral neuro pathies involving a distal-proximal progressive sen sory loss, pain and, less frequently, distal weakness. Less frequently, the pain has a proximal distribution in which the trunk, thighs and upper arms are particularly affected; this pattern occurs when the pathology involves the sensory ganglia. Painful focal peripheral disorders are caused by pathological processes that involve one or more peripheral nerves or nerve roots. These disorders include post herpetic neuralgia, posttraumatic neuro pathy, postsurgical neuropathy, cervical and lumbar polyradiculo pathies, pain associated with HIV infection, leprosy and diabetes mellitus, complex regional pain syndrome type 2 and trigeminal neuralgia 30 . Rare inherited channelopathies can show character istic pain distributions and triggering factors. For example, inherited erythromelalgia is due to mutations in SCN9A, which encodes the voltagegated sodium channel Na v 1.7 (involved in the generation and conduc tion of action potentials), and is characterized by pain and erythema (reddening) in the extremities, which is exacer bated by heat 31 . Paroxysmal extreme pain disorder is due to a distinct set of mutations in SCN9A that result in a proximal distribution of pain and erythema affect ing the sacrum and mandible 32 ; pain triggers in those with this condition can include mechanical stimuli. In approximately 30% of patients with idiopathic small fibre neuropathy, functional mutations of the Na v 1.7 sodium channel that result in hyperexcitable dorsal root ganglion neurons have been observed 33 .
Pain signalling changes
Peripheral neuropathy alters the electrical properties of sensory nerves, which then leads to imbalances between central excitatory and inhibitory signalling such that inhibitory interneurons and descending control systems are impaired. In turn, transmission of sensory signals and disinhibition or facilitation mechanisms are altered at the level of the spinal cord dorsal horn neurons. Indeed, preclinical studies have revealed several anato mical, molecular and electrophysiological changes from the periphery through to the central ner vous sys tem (CNS) that produce a gain of function, prov iding insights into neuropathic pain and its treatment (BOX 4) . At the periphery, spinal cord and brain, a gain of excita tion and facilitation and a loss of inhibition are apparent. These changes shift the sensory pathways to a state of hyperexcitability, and a sequence of changes over time from the periphery to the brain might contribute to the neuropathic pain state becoming chronic.
Ectopic activity in primary afferent fibres might have a key role in the pathophysiology of neuropathic pain following peripheral nerve injury. Patients with painful diabetic polyneuropathy and traumatic peripheral nerve injury showed a complete loss of ipsilateral spontaneous
Box 1 | Key terms
Action potential An electrical event in which the membrane potential of a cell in the nervous system rapidly rises and falls to transmit electrical signals from cell to cell.
Allodynia
Pain caused by a normally non-painful stimulus.
Aβ fibres
Sensory nerve fibres with a thick myelin sheath, which insulates the axon of the cell and normally promotes the conduction of touch, pressure, proprioception and vibration signals (35-90 metres per second).
Aδ fibres
Sensory nerve fibres with a myelin sheath, which insulates the axon of the cell and promotes the conduction of cold, pressure and pain signals (5-30 metres per second), that produce the acute and sharp experience of pain.
C fibres
Unmyelinated pain nerve fibres that respond to warmth and a range of painful stimuli by producing a long-lasting burning sensation due to a slow conduction speed (0.5-2 metres per second).
Chemoreceptors
Receptors that transduce chemical signals.
Complex regional pain syndromes
Also known as causalgia and reflex sympathetic dystrophy, complex regional pain syndromes are conditions that are characterized by the presence of chronic, intense pain (often in one arm, leg, hand or foot) that worsens over time and spreads in the affected area. These conditions are typically accompanied by a colour or temperature change of the skin where the pain is felt.
Conditioned pain modulation
A reduction of a painful test stimulus under the influence of a conditioning stimulus.
Dynamic mechanical allodynia
A type of mechanical allodynia that occurs when pain is elicited by lightly stroking the skin.
Expectancy-induced analgesia
A reduction of pain experience due to anticipation, desire and belief of hypoalgesia or analgesia.
Hyperalgesia
A heightened experience of pain caused by a noxious stimulus.
Hypoalgesia
A decreased perception of pain caused by a noxious stimulus.
Mechanoreceptors
A sensory receptor that transduces mechanical stimulations.
Nociceptors
A peripheral nervous system receptor that is responsible for transducing and encoding painful stimuli.
Paradoxical heat sensation
An experienced sensation of heat provoked by a cold stimulus.
Provoked pain
Pain provoked by applying a stimulus.
Pruriceptors
Sensory receptors that transduce itchy sensations.
Second-order nociceptive neurons
Nociceptive neurons in the central nervous system that are activated by the Aβ, Aδ and C afferent fibres and convey sensory information from the spinal cord to other spinal circuits and the brain.
Static pain
Another kind of mechanical hyperalgesia in those with neuropathic pain when pain is provoked after gentle pressure is applied on the symptomatic area.
Temporal summation
The phenomenon in which progressive increases in pain intensity are experienced during the repetition of identical nociceptive stimuli.
Thermoreceptors
Sensory receptors that respond to changes in temperature.
and evoked pain when treated with a peripheral nerve block (with lidocaine, which blocks voltagegated sodium channels) 34 . Similarly, a blockade of the dor sal root ganglion by intraforaminal epidural admin istration of lidocaine resulted in relief of painful and nonpainful sensations in patients with phantom limb pain 35 . Microneurography studies have also identified a spontaneous activity -primarily in C fibres -that is related to pain, suggesting a potential peripheral mechanism for neuropathic pain 36, 37 . Overall, the underlying hyperexcitability in neuro pathic pain results from changes in ion channel function and expression, changes in secondorder noci ceptive neuronal function and changes in inhibitory interneuronal function.
Ion channel alterations. Neuropathy causes alter ations in ion channels (sodium, calcium and potassium) within the affected nerves, which can include all types of afferent fibres that then affect spinal and brain sen sory signalling. For example, increased expression and function of sodium channels at the spinal cord termi nus of the sensory nerves (mirrored by an enhanced expression of the α 2 δ subunit of calcium channels) alters transduction and transmission due to altered ion channel function. These alterations affect spinal cord activity, leading to an excess of excitation coupled with a loss of inhibition. In the ascending afferent pathways, the sensory components of pain are via the spinothalamic pathway to the ventrobasal medial and lateral areas (1), which then project to the somatosensory cortex allowing for the location and intensity of pain to be perceived (2). The spinal cord also has spinoreticular projections and the dorsal column pathway to the cuneate nucleus and nucleus gracilis (3). Other limbic projections relay in the parabrachial nucleus (4) before contacting the hypothalamus and amygdala, where central autonomic function, fear and anxiety are altered (5). Descending efferent pathways from the amygdala and hypothalamus (6) drive the periaqueductal grey, the locus coeruleus, A5 and A7 nuclei and the rostroventral medial medulla. These brainstem areas then project to the spinal cord through descending noradrenaline (inhibition via α 2 adrenoceptors), and, in neuropathy, there is a loss of this control and increased serotonin descending excitation via 5-HT 3 receptors (7 lead to increased excitability, signal transduction and neurotransmitter release. Indeed, the crucial role of sodium channels is shown by loss or gain of pain in humans with inherited channelopathies 31 . At the same time, a loss of potassi um channels that normally modu late neural activity is also evident. If an afferent fibre is dis connected from the periphery due to an injury or a lesion, there will be sensory loss. However, the rem nants of the fibres at the injury site can generate ectopic activity (for example, neuroma C fibre afferents), and so pain from a 'numb' area results 38 . The remaining intact fibres are hyperexcitable, socalled irritable nocicep tors 39 . As a result, the patient can experience ongoing pain, numbness and evoked pains. The altered inputs into the spinal cord coupled with increased calcium channel function (through higher expression in the nerve terminal) result in increased neurotransmitter release and enhanced excitatory synaptic transmission in the nociceptive circuit.
Potential reorganization
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Dorsal root ganglion
Descending controls
Second-order nociceptive neuron alterations. Enhanced excitability of spinal neurons produces increased responses to many sensory modalities, enables low threshold mechanosensitive Aβ and Aδ afferent fibres to activate secondorder nociceptive neurons (which convey sensory information to the brain) and expands their receptive fields so a given stimulus excites more secondorder nociceptive neurons, generating the socalled central sensitization 40, 41 . In particular, ongoing discharge of peripheral afferent fibres with concomitant release of excitatory amino acids and neuro peptides leads to postsynaptic changes in secondorder nocicep tive neurons, such as an excess of signalling due to phos phorylation of Nmethyldaspartate (NMDA) and αamino 3hydroxy5methyl4 isoxazolepropionic acid (AMPA) receptors. These secondorder changes plausibly explain physical allodynia and are reflected by enhanced sensory thalamic neuronal activity, as supported by data from animal 42 and human studies 43 . Hyperexcitability can also be caused by a loss of γaminobutyric acid (GABA) releasing inhibitory interneurons that can also switch to exert consequently excitatory actions at spinal levels 44 . In addition, there are less wellunderstood functional changes in non neuronal cells within the spinal cord, such as microglia and astrocytes, which contribute to the development of hypersensitivity 45 .
Inhibitory modulation changes.
In addition to changes in pain transmission neurons, inhibitory interneurons and descending modulatory control systems are dysfunc tional in patients with neuropathic pain. Interneuron dysfunction contributes to the overall altered balance between descending inhibitions and excitations; specifi cally, neuropathy leads to a shift in excitation that now dominates. Consequently, the brain receives altered and abnormal sensory messages. Altered projections to the thalamus and cortex and parallel pathways to the lim bic regions account for high pain ratings and anxiety, depression and sleep problems, which are relayed as painful messages that dominate limbic function.
Areas such as the cingulate cortex and amygdala have been implicated in the ongoing pain state and comorbid ities associated with neuropathic pain 46 . Projections from these forebrain areas modulate descending con trols running from the periaqueductal grey (the primary control centre for descending pain modulation) to the brainstem and then act on spinal signalling. Indeed, numerous studies have shown that the brainstem excita tory pathways are more important in the maintenance of the pain state than in its induction.
Noradrenergic inhibitions, mediated through α 2 adrenergic receptors in the spinal cord, are attenuated in neuropathic pain, and enhanced serotonin signal ling through the 5HT 2 and 5HT 3 serotonin receptors becomes dominant. The noradrenergic system medi ates the diffuse noxious inhibitory controls (DNICs), the animal counterpart of the human conditioned pain modu lation (CPM ; FIG. 3) , in which one pain inhib its another through descending pathways. DNICs (and CPM) are lost or at least partially impaired in those with neuropathy. Animals that recruit noradrenergic inhib itions have markedly reduced hypersensitivity after neuropathy despite identical levels of nerve damage 47 , explaining the advantage of using medication that manipulates the monoamine system to enhance DNICs in patients by blocking descending facilitations.
Pain modulation mechanisms
Some patients with neuropathic pain are moderately affected, whereas others experience debilitating pain. Moreover, patients show a large variability in response to distinct pharmacological (in terms of type and dose) and nonpharmacological treatments. A key factor in this variability might be the way that the pain message is modulated in the CNS. The pain signal can be augmented or reduced as it ascends from its entry port (the dorsal horn), relayed to the CNS and arrives at the cerebral cortex (the area crucial for conscious ness). The various pathways and interference can, accordingly, modify the assumed correlation between the extent of the peripheral pathology and the extent of the pain syndrome. Most patients with neuropathic pain express a pro nociceptive pain modulation profile -that is, pain messages are augmented in the CNS 48 . Thus, the perception of pain can be disinhibited owing to decreased descending endogenous inhibition, which is depicted by lessefficient CPM
, facilitated through sensitization of ascending pain pathways, which is depicted by enhanced temporal summation of painful stimulations, or both. Temporal summation is augmented in neuropathic and nonneuropathic pain, but patients with neuro pathic pain present with a higher slope of increase 48 . CPM has been shown to be less effi cient in patients with various pain syndromes than in healthy controls 49 .
The prospect of harnessing pain modulation seems promising for a more individualized approach to pain management. Indeed, studies have shown that the pain modulation profile can predict the develop ment and extent of chronic postoperative pain [50] [51] [52] . If these findings are confirmed by larger studies, we can speculate that patients who express a facilitatory pro nociceptive profile could be treated with a drug that reduces the facilitation (such as gabapentinoids) and patients who express an inhibitory pronociceptive pro file could be treated with a drug that enhances the inhib itory capacity (for example, serotonin-noradrenaline reuptake inhibitors) 50 . Patients who express both less efficient CPM and enhanced temporal summation might need a combination of treatments. Indeed, the level of CPM predicts the efficacy of duloxetine (a selective serotonin-noradrenaline reuptake inhibitor) in patients; CPM is restored with both duloxetine and tapen tadol (a noradrenaline reuptake inhibitor). Moreover, the altered pain modulation profile of a patient can be reversed towards normality when pain is treated, as exemplified with arthroplasty surgery in patients with osteoarthritis; when the diseased joint is replaced, the majority of patients will be free of pain and the central and peripheral processes normalize 34, 53, 54 . Notably, pain modulation is highly influenced by expectancyinduced analgesia, in which changes due to the beliefs and desires of patients and providers 55 affect response to treatment for neuropathic pain. In lab oratory settings, expectancyinduced analgesia influences clin ical pain in irritable bowel syndrome [56] [57] [58] , idiopathic and neuropathic pain 59 . For example, Petersen et al. 60, 61 tested expectancyinduced analgesia in patients who developed neuropathic pain after thoracotomy. Patients received 
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Within the facial or intra-oral trigeminal nerve territory Trigeminal neuralgia* Central neuropathic pain associated with multiple sclerosis Unilateral distribution in one or more spinal dermatome or the trigeminal nerve territory (usually the ophthalmic division)
Postherpetic neuralgia
In the innervation territory of the injured nerve, typically distal to a site of surgery, trauma or compression
Peripheral nerve injury pain
In the missing body part or residual limb
Post-amputation pain
In the feet and often the lower legs, thighs and hands
Painful polyneuropathy
In the innervation territory of the affected nerve root lidocaine in an open (that is, patients were told: "The agent you have just been given is known to powerfully reduce pain in some patients") or hidden ("This is a control condition for the active medication") manner in accord ance with a previously described protocol 62 ; the results showed a large reduction of ongoing pain, maximum winduplike pain and an area of hyper algesia in those in the open group, recapitulating previous reports 59, 60 . These findings point to a clinically relevant endogenous pain inhibitory mechanism with implications for phenotyping patients with neuropathic pain in clinical trial designs and practices. Such effects should be reduced in clinical trials and intentionally enhanced in daily clinical practices as a strategy to optimize pain management.
Diagnosis, screening and prevention A system was proposed to determine the level of certainty with which the pain in question is neuropathic as opposed, for example, to nociceptive pain 5 (FIG. 4a) . If the patient's history suggests the presence of a neuro logical lesion or disease and the pain could be related to such (for example, using validated screening tools) and the pain distribution is neuroanatomically plausible, the pain is termed 'possible' neuropathic pain. 'Probable' neuro pathic pain requires supporting evidence obtained by a clinical examination of sensory signs (for example, bed side testing and quantitative sensory testing). 'Definite' neuropathic pain requires that an objective diagnostic test confirms the lesion or disease of the somato sensory nervous system (for example, neurophysiological tests and skin biopsy). A minimum finding of probable neuropathic pain should lead to treatment.
On the basis of the assumption that characteristic qualities indicative of neuropathic pain in sensory per ception are present, several screening tools have been developed to identify neuropathic pain conditions or neuro pathic components to chronic pain syndromes 63
. These simple to use patientreported ques tionnaires, for example, the DN4 or painDETECT 22, 64 , assess character istic neuropathic pain symptoms (such as burning, tingling, sensitivity to touch, pain caused by light pressure, electric shocklike pain, pain to cold or heat, and numbness) and can distinguish between neuro pathic and nonneuropathic pain with high specifi city and sensitivity when applied in patients with chronic pain. Other tools, such as the Neuropathic Pain Symptom Inventory (NPSI) 65 , have been more specifi cally developed for the quantification of neuropathic symptoms and dimensions and have contributed to further phenotype individual patients particularly for clinical trials.
Confirmatory tests for nerve damage
Different psychophysical and objective diagnostic tests are available to investigate somatosensory pathway func tion, including bedside evaluation and assessment of sensory signs as well as neurophysiological techniques, skin biopsy and corneal confocal microscopy (FIG. 4b) . Of these, sensory evaluation, neurophysiological techniques and quantitative sensory testing are routinely used.
Bedside sensory assessment of sensory signs. Neuropathic pain presents as a combination of differ ent symptoms and signs 66 . Touch, pinprick, pressure, cold, heat, vibration, temporal summation and after sensations can be examined at the bed side, whereby the patient describes the sensation after a precise and reproducible stimulus is applied 67 . To assess either a loss (negative sensory signs) or a gain (positive sensory signs) of somatosensory function, the responses are graded as normal, decreased or increased. The stimulus evoked (positive) pain types are classified as hyper algesic (experi encing increased pain from a stimulus that is normally perceived as less painful) or allodynic (experi encing pain from a stimulus that does not normally trigger a pain response), and according to the dynamic or static character of the stimulus.
Quantitative sensory testing. Quantitative sensory tests use standardized mechanical and thermal stimuli to test the afferent nociceptive and nonnociceptive systems in the periphery and the CNS. Quantitative sensory tests assess loss and gain of function of the entire different afferent fibre classes (Aβ, Aδ and C fibres), which is a distinct advantage over other methods 68 . The German Research Network on Neuropathic Pain 69 proposed a battery of quantitative sensory tests that consists of 13 parameters to help identify somatosensory pheno types of patients with neuropathic pain. These ther mal and mechanical tests include the determination of detection thresholds for cold, warm, paradoxical heat sensations and touch and vibration; determination of pain thresholds for cold and heat stimulations, pinprick and blunt pressure; and determination of allodynia and pain summation. Recently, normative data from a large database of healthy individuals have helped to determine gain or loss of sensory function in agematched and sex matched patients with neuropathic pain 70, 71 . Accordingly, pathological values of positive and negative signs have been determined for most variables (FIG. 5) .
Box 3 | Neuropathic pain and diabetes mellitus
Painful chronic neuropathy in patients with diabetes mellitus ranges from 10% to 26% 38 . Although risk factors and potential mechanisms underlying neuropathy have been studied extensively, the aetiology of the painful diabetic neuropathy is not completely known. However, findings from epidemiological studies have suggested that patients with diabetes mellitus who develop neuropathy, compared with those patients who do not, seem to have different cardiovascular function, glycaemic control, weight, rates of obesity, waist circumference, risk of peripheral arterial disease and triglyceride plasmid levels. Indeed, patients with diabetes mellitus have alterations in the peripheral and central pain pathways; other mechanistic contributors include blood glucose instability, increased peripheral nerve epineural blood flow, microcirculation of the skin of the foot, altered intraepidermal nerve fibre density, increased thalamic vascularity and autonomic dysfunction. Furthermore, methylglyoxal (a by-product of glycolysis) plasma levels are increased in patients with diabetes mellitus owing to excessive glycolysis and decreased degradation by the glyoxalase system 197 . This metabolite activates peripheral nerves by changing the function of Na v 1.7 and Na v 1.8 voltage-gated sodium channnels 197 and might, therefore, have a role in painful neuropathy. Studies in animals have shown that methylglyoxal slows nerve conduction, heightens calcitonin gene-related peptide release from nerves and leads to thermal and mechanical hyperalgesia 197 . Notably, methylglyoxal-dependent modifications of sodium channels induce diabetes-associated hyperalgesia that is not simply due to changes in peripheral fibres 197 .
Neurophysiological techniques. Laserevoked potentials (LEPs) are widely considered the most reliable neuro physiological tool to assess nociceptive functions 67, 72 . For example, nerve conduction studies, trigeminal reflexes and somatosensoryevoked potentials -the Aβ fibre mediated standard neurophysiological techniquesdo not provide information on nociceptive pathways. However, they are still useful to identify damage along the somatosensory pathways and are widely used for assessing peripheral and CNS diseases that cause neuro pathic pain 73 . Laser stimulations selectively activate Aδ and C nociceptors in the superficial layers of the skin 74 . LEPs related to Aδ fibre activation have been stan dardized for clinical application. The responses to stimulation are recorded from the scalp and consist of waveforms with different latencies. In diseases associ ated with damage to the nociceptive pathway, LEPs can be absent, reduced in amplitude or delayed in latency [75] [76] [77] . Among nociceptiveevoked potentials, contact heat evoked potentials are also widely used in assessing neuro pathic pain 78 . Concentric electrodes have also been introduced to measure painrelated evoked potentials and the smallfibre involvement in neuropathic pain 79 . Nevertheless, some studies suggest that concentric elec trodes also activate nonnociceptive Aβ fibres; hence, painrelated evoked potential recording is not suitable for assessing nociceptive systems 78 .
Skin biopsy. Skin biopsy to assess epidermal innerva tion is regarded as the most sensitive tool for diagnos ing smallfibre neuropathies 80 . The technique is useful because the skin has widespread unmyelinated C fibre terminals, with relatively few small myelinated Aδ fibres that lose their myelin sheath and reach the epidermis as unmyelinated free nerve endings 81, 82 . However, the relation ship between skin biopsy data and neuropathic pain is still unclear. One study in 139 patients with peripheral neuropathy suggested that a partial sparing of intraepidermal nerve fibres, as assessed with skin biopsy, is associated with provoked pain 83 .
Corneal confocal microscopy. As a noninvasive in vivo technique, corneal confocal microscopy can be used to quantify corneal nerve fibre damage (to small myelinated Aδ and unmyelinated C fibres) in patients with periph eral neuropathies 84, 85 . However, this technique has several limitations, such as the high cost and the reduced avail ability in most clinical centres. Furthermore, whether some conditions (such as dry eye syndrome and Sjögren syndrome, eye diseases or previous eye surgery) influence the corneal confocal variables is still unclear 86 . No study has reliably investigated the association between corneal confocal microscopy variables and neuropathic pain.
Prevention
Given that the available treatments for neuropathic pain have meaningful but modest benefits (see Management) , interventions that prevent neuropathic pain can have a substantial effect on public health. Indeed, increased attention to prevention has the potential to reduce the disability experienced by many patients with chronic neuropathic pain. Leading a healthy lifestyle and edu cation regarding paincausing health conditions are important components of prevention, especially in those who are at greater risk of developing neuropathic pain 87 . Prevention programmes that combine mutually reinforcing medical and behavioural interventions might lead to greater preventive benefits.
The identification of risk factors is essential to pre vent neuropathic pain developing in atrisk individ uals. Primary prevention strategies (in generally healthy but atrisk individuals) include the live attenuated 88, 89 and subunit adjuvanted 90, 91 herpes zoster vaccines, which both reduce the likelihood of developing herpes zoster infections in individuals ≥50 years of age [88] [89] [90] [91] , and there fore, reduce the likelihood of postherpetic neural gia. Secondary prevention involves administering pre ventive interventions to individuals who are experi encing an illness, injury or treatment that can cause chronic neuropathic pain. Examples of this approach include the perioperative treatment of surgical patients
Box 4 | Challenges in translating animal studies to therapeutic pharmacological targets in humans
Translating knowledge from preclinical observations in animal models to new targeted drug therapies in the clinic has been challenging. The differences between animal behavioural tests and human neuropathic pain features, lack of long-term efficacy data in animal models and the homogeneity of animal genetic strains might contribute to these challenges. Nonetheless, a substantial part of our knowledge of neuropathic pain mechanisms is derived from animal studies. Animal models of neuropathic pain use surgical lesions of the spinal cord, cranial and peripheral sensory nerves, such as ligation, constriction or transection of parts or branches of nerves 198 . These animal models exhibit hypersensitivity to external stimuli, commonly to mechanical stimuli as assessed with von Frey hairs (for measuring the tactile sensitivity), but may also include hypersensitivity to thermal stimuli (especially cold). Higher-level outcome measurements that are suggestive of reward from pain relief and reflective of the spontaneous pain experienced by patients have recently been introduced in the array of animal models of neuropathic pain 199 . Models of diabetic neuropathy have also been affected by the ill health of the animals, but this aspect is starting to be addressed in the most recent studies 38 . Notably, basic research findings have often led to the development of specific therapeutic targets. For example, the altered function of the sodium channels within the damaged peripheral nerves provides insights into the use of topical voltage-gated sodium channel blockade (such as lidocaine 107 and carbamazepine 186 ) for neuropathic pain. Moreover, the assumption of abnormal sodium channel activity has led to the use of oxcarbazepine, which has been shown to be more effective in patients with the 'irritable nociceptor' phenotype 186 . Drugs such as gabapentin and pregabalin 200 (see Management) target the α 2 δ subunit of the voltage-dependent calcium channels that are overexpressed in patients with neuropathic pain. When given intrathecally, gabapentin inhibited hypersensitivity in animal models 201 but has failed to show positive results in humans 202 .
to prevent chronic postsurgical pain 92 and the use of antiviral or analgesic treatment in patients with herpes zoster infection 93 . Furthermore, proper management of health con ditions, such as diabetes mellitus, may prevent neuropathic pain before it even presents 94 .
Management
The management of neuropathic pain generally focuses on treating symptoms because the cause of the pain can be rarely treated; furthermore, the management of aetio logical conditions, such as diabetes mellitus, is typically insufficient to relieve neuropathic pain. Patients with neuropathic pain generally do not respond to analgesics such as acetaminophen, NSAIDs or weak opioids such as codeine. The traditional approach to the management of a patient with neuropathic pain is to initiate treatment with conservative pharmacological and complementary therapies before interventional strategies, such as nerve blocks and neuromodulation, are used. However, the limited efficacy of the drugs, the ageing population of patients, polypharmacy in elderly patients and opioid related adverse effects have resulted in an increasing use of interventional therapies. Clinical studies are lacking to help guide the physician in the optimal sequence of therapy in a given patient.
Medical intervention
Numerous therapeutic recommendations, with dif ferent classes of drug, for neuropathic pain have been proposed [95] [96] [97] [98] [99] . On the basis of a systematic review and metaanalysis of all drug studies reported on since 1966, including unpublished trials 100 , pregabalin (a GABA analogue), gabapentin (a GABA inhibitor), duloxetine (a serotonin-noradrenaline reuptake inhibitor) and vari ous tricyclic antidepressants have strong recommenda tions for use and are recommended as firstline treatments for peripheral and central neuropathic pain. High concentration capsaicin (the active component of chili peppers) patches, lidocaine patches and tramadol (an opi oid with serotonin and noradrenaline reuptake inhibition effects) have weak evidence in support of their use and are recommended as secondline treatments for periph eral neuropathic pain only. Strong opioids and botulinum toxin A (administered by specialists) have weak recom mendations for use as thirdline treatments. However, most of these treatments have moderate efficacy based on the number needed to treat (NNT; that is, the number of patients necessary to treat to obtain one responder more than the comparison treatment, typically placebo) for obtaining 50% of pain relief 101 (TABLE 1) . Furthermore, pharmacological treatments for chronic neuropathic pain are effective in <50% of patients and may be associated with adverse effects that limit their clinical utility 101 .
First-line treatments. Antidepressants and antiepileptics have been the most studied drugs in neuropathic pain. Among antidepressants, tricyclic antidepressants, such as amitriptyline, and serotonin-noradrenaline reuptake inhibitors, such as duloxetine, have confirmed efficacy in various neuropathic pain conditions. Their analge sic efficacy seems largely mediated by their action on descending modulatory inhibitory controls, but other mechanisms have been proposed (including an action on β 2 adrenoceptors) 102 . Among antiepileptics, the effi cacy of pregabalin and gabapentin, including extended release formulations, is best established for the treatment of peripheral neuropathic pain and, to a lesser extent, spinal cord injury pain. However, the number of negative trials has increased over the past 5 years. The analgesic effects of these drugs are mainly related to a decrease in central sensitization through binding to the α 2 δ subunit of calcium voltagegated channels 103 . Combination of pregabalin or gabapentin with a tri cyclic antidepressant or opioid at lower doses has resulted in beneficial effects as compared to mono therapy in peripheral neuropathic pain 100, 101, 104 . However, the effi cacy and adverse effects of highdose mono therapy were similar to those of moderatedose combin ation therapy in patients with diabetic neuropathic pain who did not respond to monotherapy at moderate doses 105 . These studies provide a rationale for the use of combin ations of drugs, at moderate dosages, in patients who are unable to tolerate highdose monotherapy.
Second-line treatments.
Lidocaine is thought to act on ectopic neuronal discharges through its sodium channelblocking properties. The efficacy of lidocaine 5% patches has been assessed in focal peripheral post herpetic neuralgia, but their therapeutic gain is modest compared with placebo 106, 107 . Capsaicin initially activates transient receptor potential cation channel subfamily V Nature Reviews | Disease Primers . A test stimulus can be a thermal contact stimulation (1), mechanical pressure (2), an electrical stimulus (3) -for each, either pain threshold or suprathreshold magnitude estimation can be used -or nociceptive withdrawal reflex (4). A typical conditioning stimulus consists of thermal contact stimulation (5), or immersion in a cold (6) or hot (7) water bath. Other modalities can be used as well. During a CPM assessment, a test stimulus is given first, then the conditioning stimulus is given, and the test is repeated during or immediately after the conditioning. member 1 (TRPV1) ligandgated channels on noci ceptive fibres, leading to TRPV1 desensitization and defunctionalization. The sustained efficacy of a single application of a highconcentration capsaicin patch (8%) has been reported in postherpetic neuralgia 108 , as well as diabetic 104 and nondiabetic painful neuropathies 109 . The longterm safety of repeated applications seems favourable based on open studies, but there are no long term data on the effects on epidermal nerve fibres in patients with neuropathic pain 101 . Tramadol, an opioid agonist and serotonin-noradrenaline reuptake inhibitor, has also been shown to be effective, mainly in periph eral neuropathic pain; its efficacy is less established in central neuropathic pain 101 .
Third-line treatments. Botulinum toxin A is a potent neurotoxin commonly used for the treatment of focal muscle hyperactivity and has shown efficacy of repeated administrations over 6 months, with enhanced effects of the second injection 110 . The toxin has a beneficial role in the treatment of peripheral neuropathic pain (for example, diabetic neuropathic pain, postherpetic neuralgia and trigeminal neuralgia) [110] [111] [112] .
Opioid agonists, such as oxycodone and morphine, are mildly effective 101 , but there is concern about pre scription opioidassociated overdose, death, diversion, misuse and morbidity 113 . There are weak, negative or inconclusive recom mendations for the use of all other drug treatments for neuropathic pain in general. Antiepileptics other than α 2 δ ligands (for example, topiramate, oxcarbazepine, carbamazepine, valproate, zonisamide, lacosamide and levetiracetam) fall into these categories, although some agents are probably effective in subgroups of patients. Oromucosal cannabinoids have been found to be vari ably effective in pain associated with multiple sclerosis and in peripheral neuropathic pain with allodynia, but several unpublished trials were negative on the primary outcome. Results for selective serotonin reuptake inhib itors, NMDA antagonists, mexiletine (a nonselective voltagegated sodium channel blocker) and topical cloni dine (an α 2 adrenergic agonist and imidazoline receptor agonist) have generally been inconsistent or negative except in certain subgroups.
Emerging treatments.
A few drugs targeting novel mechanisms of action are under clinical development for the treatment of peripheral neuropathic pain. These include, in particular, subtype selective sodium channel blocking agents, particularly Na v 1.7 antagonists 114 , and EMA401, a novel angiotensin type II antagonist that has been found to be effective in a phase II clinical trial in postherpetic neuralgia 115 . Although still in the pre clinical phase, studies show promising results of stem cell treatment for neuropathic pain 116, 117 .
Interventional therapies
Interventional treatments, such as nerve blocks or sur gical procedures that deliver drugs to targeted areas, or modulation of specific neural structures, provide alternative treatment strategies in selected patients || 'Definite' neuropathic pain refers to a pain that is compatible with the features of neuropathic pain and confirmatory tests are consistent with the location and nature of the lesion or disease, although this may not imply any causality. b | The confirmatory tests for neuropathic pain include quantitative sensory testing (in which the patient provides a subjective report on a precise and reproducible stimulus), blink reflex testing (whereby the trigeminal afferent system is investigated by recording the R1 and R2 reflex responses recorded from the orbicularis oculi muscle) and nerve conduction study (which assesses non-nociceptive fibre function of the peripheral nerves). Somatosensoryevoked potentials (N9 is generated by the brachial plexus and N20 by the somatosensory cortex) and laser-evoked potentials (LEPs), both recorded from the scalp, are neurophysiological tools that investigate large and small afferent fibre function. The N1 LEP wave is a lateralized component and generated by the secondary somatosensory cortex, and the negative-positive complex of LEP (N2-P2) is a vertex recorded potential, which is generated by the insular cortex bilaterally and the cingulate cortex 204 . A skin biopsy enables the quantification of the intraepidermal nerve fibres, which provides a measure of small-fibre loss 77 . Finally, corneal confocal microscopy assesses corneal innervation, which consists of small nerve fibres. In most patients with neuropathic pain, standard neurophysiological testing, such as blink reflex, nerve conduction study and somatosensoryevoked potentials, is sufficient for showing the damage of the somatosensory system. However, in patients with selective damage of the nociceptive system, a nociceptivespecific tool, such as LEPs, skin biopsy or corneal confocal microscopy, is needed. Typically, tests are performed in the sequence of increasing invasiveness; that is, quantitative sensory testing, blink reflex, nerve conduction study, somatosensory-evoked potentials, LEPs, skin biopsy and corneal confocal microscopy. SNAP, sensory nerve action potential. Adapted with permission from REF. 77 with refractory neuropathic pain 118, 119 (FIG. 6) . Although generally safe (see below), spinal cord stimulation and peripheral nerve stimulation have been associated with hardwarerelated, biological complications, such as infec tions and programmingrelated or treatmentrelated adverse effects (including painful paraesthesias) 120, 121 .
Neural blockade and steroid injections.
A perineural injection of steroids provides transient relief (1-3 months) for traumarelated and compressionrelated peripheral neuropathic pain 122 . Systematic reviews and metaanalysis of epidural steroid injections for the treatment of cervical and lumbar radiculopathies indicate an immediate mod est reduction in pain and function of <3 months duration, but had no effects on reducing the risk for subsequent sur gery 119, 123, 124 . Epidural local anaesthetic and steroid nerve blocks were given a weak recommendation for the treat ment of lumbar radiculopathy and acute zoster associated neuropathic pain 119 . Although sympathetic ganglion blocks have been used to treat pain in some patients with complex regional pain syndromes (also known as causal gia and reflex sympathetic dystrophy), the evidence for longterm benefit is weak 119 .
Spinal cord stimulation. Lowintensity electrical stimulation of large myelinated Aβ fibres was intro duced based on the gate control theory 125 as a strat egy to modu late the pain signals transmitted by the unmyelinated C fibres. The most commonly used and the best studied neuromodulation strategy has been spinal cord stimulation, in which a monophasic square wave pulse (frequency ranging 30-100 Hz) is applied, resulting in paraesthesia in the painful region 126 . Newer stimulation parameters, such as burst (40 Hz burst with five spikes at 500 Hz per burst) and highfrequency (10 kHz with sinusoidal waveforms) spinal cord stimu lation, provide paraesthesia free stimulation and equiva lent or better pain relief compared with the monophasic squarewave pulse 127, 128 . The relative safety and reversibility of spinal cord stimulation, as well as its costeffectiveness over the long term have made it an attractive strategy for managing patients with refractory chronic neuropathic pain [129] [130] [131] . Systematic reviews, randomized controlled trials and several case series provide evidence for the longterm efficacy of spinal cord stimulation when com bined with medical treatment compared with medical manage ment in various pain neuropathies [132] [133] [134] , and has been shown to offer sustained results at 24 months of treatment 135, 136 . Two randomized trials in individ uals with painful diabetic neuropathy reported greater reduction in pain and improvements in measures of quality of life compared with controls 137, 138 . Current European guidelines provide a weak recommenda tion for spinal cord stimulation (combined with med ical treatment) in, for example, diabetic neuropathic 118, 119, 139 . The success of spinal cord stimulation for neuropathic pain may depend on the appropri ate selection of patients based on psychological traits, sensory phenotype, enhanced central sensitization and reduced CPM 140, 141 . Dorsal root ganglion, peripheral nerve and peripheral nerve field stimulation. Neurostimulation of afferent fibres outside the spinal cord (for example, the dorsal root ganglion, which contains the cell bodies of sen sory neurons, and peripheral nerves) and subcutaneous peripheral nerve field stimulation have been reported to provide pain relief in various chronic neuropathic pain states, including occipital neuralgia and postherpetic neuralgia 142, 143 . A multicentre prospective cohort study in patients with chronic neuropathic pain reported that dorsal root ganglion stimulation provided 56% pain reduction with a 60% responder rate (>50% reduction in pain) 144 . These preliminary observations are being examined with controlled trials.
Epidural and transcranial cortical neurostimulation.
Epidural motor cortex stimulation (ECMS), repetitive transcranial magnetic stimulation (rTMS) and trans cranial direct current stimulation (tDCS) of the pre central motor cortex at levels below the motor threshold have been proposed as treatment options for patients with refractory chronic neuropathic pain [145] [146] [147] . Cortical neurostimulation may reduce painrelated thalamic hyperactivity or activate descending inhibitory path ways. Metaanalysis reports suggest that 60-65% of patients respond (>40% pain reduction) to EMCS 147 . ECMS is a neurosurgical procedure that requires precise intra operative placement of the stimulating electrode No overall impairment of sensory evaluation after repeated applications and caution should be taken in progressive neuropathy
Opioids
Tramadol μ-Receptor agonist and monoamine reuptake inhibition 4.7 (3.6-6.7) Nausea, vomiting, constipation, dizziness and somnolence
History of substance abuse, suicide risk and use of antidepressant in elderly patients
Morphine and oxycodone μ-Opioid receptor agonists; oxycodone might also cause κ-opioid receptor antagonism 4.3 (3.4-5.8) Nausea, vomiting, constipation, dizziness and somnolence
History of substance abuse, suicide risk and risk of misuse in the long term
Neurotoxin
Botulinum toxin A Acetylcholine release inhibitor and neuromuscular-blocking agent; potential effects on mechanotransduction and central effects in neuropathic pain 1.9 (1.5-2.4) Pain at injection site Known hypersensitivity and infection of the painful area *Number needed to treat (NNT) for 50% pain relief represents the number of patients necessary to treat to obtain one responder more than the comparison treatment, typically placebo
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over the motor cortex region corresponding to the painful body part for optimal outcome. rTMS and tDCS are noninvasive therapies that involve neurostimulation of brain areas of interest via magnetic coils or electrodes on the scalp. Repetitive sessions (5-10 sessions over 1-2 weeks) with high frequency rTMS (5-20 Hz) have shown benefits in a mixture of central, peripheral and facial neuropathic pain states, with effects lasting >2 weeks after the stimulation. tDCS has been reported to be beneficial in redu cing several peripheral neuropathic conditions 148 . Current European guidelines include a weak recommendation for the use of EMCS and rTMS in refractory chronic neuropathic pain and tDCS for peripheral neuropathic pain 133 . Contraindications of rTMS include a history of epilepsy and the presence of aneurysm clips, deep brain electrodes, cardiac pacemakers and cochlear implants.
Deep brain stimulation.
The use of longterm intra cranial stimulation for neuropathic pain remains contro versial. Multiple sites for deep brain stimulation, including the internal capsule, various nuclei in the sensory thalamus, periaqueductal and peri ventricular grey, motor cortex, septum, nucleus accumbens, pos terior hypothalamus and anterior cingulate cortex, have been examined as potential brain targets for pain control 149 . The UK National Institute for Health and Care Excellence (NICE) guidelines recognize that the pro cedure can be efficacious in some patients who are refractory to other forms of pain control, but current evidence on the safety of deep brain stimulation shows signifi cant potential risks, such as intraoperative seizure, lead fractures and wound infections 98 . Contrary to the NICE guidelines, the current European guidelines give inconclusive recommendations 139 .
Intrathecal therapies. Intrathecal therapies have been developed to deliver drugs to targeted nerves through an implanted and refillable pump in patients with severe and chronic pain that is refractory to conservative treat ments, including psychological, physical, pharmaco logical and neuromodulation therapies 150, 151 . The report from the 2012 Polyanalgesic Consensus Conference highlighted that this therapy is associated with risks of serious morbidity and mortality and made recommen dations to reduce the incidence of these serious adverse effects 152 . The only US FDAapproved drugs for use with such devices are morphine and ziconotide (an Ntype calcium channel antagonist) 153 . The most frequently reported adverse reactions associated with intrathecal ziconotide are dizziness, nausea, confusion, memory impairment, nystagmus (uncontrolled movement of the eyes) and an increase in the levels of serum creatine kinase. Ziconotide is contraindicated in patients with a history of psychosis, and patients should be monitored for evidence of cognitive impairment, hallucinations or changes in mood and consciousness. No highquality randomized trials have been conducted to assess the efficacy of ziconotide and morphine; hence, the recom mendations are a consensus of experts based on clinical experience or case series.
Physical therapies
Physical therapy, exercise and movement representation techniques (that is, treatments such as mirror therapy and motor imagery that use the observation and/or imagination of normal painfree movements) have been suggested to be beneficial in neuropathic pain manage ment 154, 155 . For example, mirror therapy and motor imagery are effective in the treatment of pain and dis ability associated with complex regional pain syndrome type I and type II 156 . The quality of evidence supporting these interventions for neuropathic pain is weak and needs further investigation 154, 157 .
Psychological therapies
People with chronic pain are not passive; they actively attempt to change the causes of pain and change their own behaviour in response to pain. However, for many patients, such change without therapeutic help is unachievable, and repeated misdirected attempts to solve the problem of pain drive them further into a cycle of pain, depression and disability 158 . At present, there is no evidence for identifying who is at risk of untreatable, difficult to manage neuropathic pain and who might benefit from psychological intervention, although research is underway on the former 159 . Psychological interventions are designed to promote the management of pain and to reduce its adverse con sequences. Treatments are often provided after pharma cological or physical interventions have failed, although they could be introduced earlier and in concert with nonpsychological interventions. Cognitive-behavioural therapy (CBT) has received the most research atten tion; however, CBT is not a single treatment and can be usefully thought of as a family of techniques that are woven together by a clinical narrative of 'individ ual change' delivered by therapists who actively manage treatment. Such treatments address mood (typically anxiety and depression), function (including disability) and social engagement, as well as indirectly targeting analgesia. Secondary outcomes are sometimes reported because they are deemed important to treatment deliv ery (for example, therapeutic alliance and selfefficacy) or because they are valued by one or more stakeholder (for example, return to work and analgesic use).
A Cochrane systematic review of psychological inter ventions for chronic pain analysed data from 35 trials, which showed smalltomoderate effects of CBT over comparisons such as education, relaxation and treatment as usual 160 . In a companion review of 15 trials delivering treatment via the Internet, a similar broadly positive con clusion emerged, although the confidence in the estim ates of effects was low 161 . Psychological treatments other than behavioural therapy and CBT were considered in this review, but none was of sufficient quality to include. Another Cochrane review of trials specifi cally undertaken in patients with neuropathic pain found no evidence for or against the efficacy and safety of psychological inter ventions for chronic neuropathic pain 162 , which is not sur prising given the similar findings for non psychological interventions 163 . An urgent need for studies of treat ments that are designed specifi cally for patients with neuropathic pain exists, in particu lar, those with pain ful diabetic neuropathy, which is a growing problem 164 . Specifically, studies of CBT are needed with content that is specifically designed to meet the psychosocial needs of patients with neuro pathy, in particular, with regard to the multiple sensory challenge, comorbidity and polypharmacy 165 . A recognition that neuropathic pain increases with age will also mean that an understand ing of laterlife accommodation to illness will be impor tant 166 . In addition, a methodological focus on individual experience and trajectories of change is needed, either through single case experiments or through ecological momentary assessment 167 . Furthermore, communication technology, in particular, the use of mobile health innova tion, is likely to play an important part in future solutions. However, how to manage effective therapeutic relation ships at a distance, and how technology can augment and improve facetoface CBT remain to be clarified 168 . Technical psycho logical variables -such as catastrophic thinking, acceptance or readiness to change -should be relegated to process variables. Conversely, a pragmatic focus on patientreported outcomes will be essential to reduce pain, improve mood and reduce disability, which will ultimately improve quality of life.
Quality of life
Neuropathic pain can substantially impair quality of life as it often associates with other problems, such as loss of function, anxiety, depression, disturbed sleep and impaired cognition. Measures of healthrelated qual ity of life (HRQOL) that capture broad dimensions of health including physical, mental, emotional and social functioning are increasingly used when assessing the efficacy of different interventions to manage chronic neuropathic and nonneuropathic pain. It is mainly use ful when calcu lating qualityadjusted life years, which are necessary for costutility analyses.
The most commonly used HRQOL instruments are general, whereas others have been designed specifically for those with neuropathic pain. MeyerRosberg and col leagues validated both the 36Item Short Form Health Survey (SF36) and the Nottingham Health Profile (NHP) in the assessment of HRQOL in neuropathic pain related to peripheral nerve or nerve root lesions in patients attending multidisciplinary pain clinics 169 . The scores of all eight dimensions (vitality, physical function ing, bodily pain, general health perceptions, physical role functioning, emotional role functioning, social role func tioning and mental health) in the SF36 were significantly lower in those with neuropathic pain than in the general population, which is in line with another study 170 . The onset of neuropathy in patients with diabetes mellitus has been shown to significantly decrease all aspects of quality of life 171 . If diabetic polyneuropathy is accompanied by pain, both physical and mental compo nents of quality of life are further affected 172 . A recent study also showed that both EuroQol five dimensions (EQ5D) and Short Form6 dimension (SF6D) ques tionnaires can discriminate between chronic pain with or without neuropathic pain 173 . Furthermore, the role of psychological factors in impairing quality of life in neuropathic pain has been analysed 174 , showing, for example, that pain catastro phizing was associated with decreased HRQOL 174 . The SF36 and the EQ5D have been the most commonly used instruments in clinical trials to assess the efficacy of treatments, such as gaba pentin in postherpetic neuralgia 175 , diabetic polyneuro pathy 176 and neuropathic pain due to peripheral nerve injury 170 ; the efficacy of duloxet ine in diabetic peripheral neuropathy 177 ; and the efficacy of spinal cord stimulation in diabetic polyneuropathy 178 .
Outlook
Although nervous system mechanisms under lying chronic neuropathic pain have been uncovered through animal and human research, the development of novel interventions with improved efficacy and toler ability has been slow. New therapeutic approaches as well as improved clinical trial designs, specifically addressing genotypic and phenotypic profiles, have great promise to build on recent advances in basic and translational research.
Clinical trial design
The explanations for the slow progress in identifying treatments with improved efficacy that are receiving the greatest attention are inadequate clinical trial assay sensitiv ity and the need to target treatment to patients who are most likely to respond 179, 180 . Assay sensitiv ity refers to the ability of a clinical trial to distinguish an efficacious treatment from placebo (or another compar ator). The possibility that recent neuropathic pain clinical trials suffer from limited assay sensitivity is consistent with the observation that a considerable number of recent trials in patients with neuropathic pain investi gating medications with wellestablished efficacy have returned negative results 7,181 . For exam ple, a recent analy sis of neuropathic pain trials showed that assay sensitivity was compromised by including patients with highly variable baseline pain ratings 182 , which suggests that trials might have greater assay sen sitivity if highly variable baseline pain ratings were an exclusion criterion 115 . The outcomes of clinical trials in neuropathic pain have generally shown modest efficacy, with the NNTs for 50% pain relief ranging from six to eight for pos itive studies in the latest metaanalysis 101 . Several reasons could account for these results 179, 181 , including high placebo responses, variability in the diagnostic criteria used for neuropathic pain in clinical trials and limited assay sensitivity. Thus, it has been proposed that an alter native therapeutic approach to neuropathic pain should incorporate stratification of patients according to clin ical phenotypes (signs and symptoms) 66, 77, 183, 184 , whereas most trials have simply classified patients according to aetiology.
Phenotyping
Several clinical trials provide support for the relevance of phenotypic subgrouping of patients, which has the potential to lead to a more personalized pain therapy in the future 107, 110, 185, 186 . In particular, two phenotypes -the presence of mechanical allodynia and preserved nociceptive function -are often combined and seem to predict the response to systemic and topical sodium channel blockers, botulinum toxin A and clonidine gel in recent clinical trials 107, 110, 185 . Indeed, any personalized pain treatments will rely on the ability to select patients who are likely to respond 187 . The strongest evidence showing that profiles of signs and symptoms can identify treatment responders stems from a trial in which patients who were defined as having an irritable nociceptor phenotype experienced a greater decrease in pain with oxcarbazepine versus placebo than those without this phenotype 186 . This is the only trial in which a prespecified primary analysis demonstrated a difference in treatment versus placebo response in patient subgroups identified by phenotyping. These results are very promising, but require replication as well as use of phenotyping measures that would be suitable for larger confirmatory trials and use in clin ical practice 188 . Phenotyping could also be used to test whether certain patients have a more robust response to nonpharmacological treatments, for example, inva sive, psychological and complementary interventions 188 , as well as to identify which patients are most likely to respond to combinations of treatments. Indeed, given the importance of expectations and psychological and social factors -including adaptive coping and catastro phizing -in the development and maintenance of chronic neuropathic pain, it would not be surprising if phenotyping has a great part to play in demonstrating the efficacy of psychological interventions as it does for medications.
To advance the design, execution, analysis and inter pretation of clinical trials of pain treatments, several public-private partnerships have undertaken system atic efforts to increase assay sensitivity and provide validated approaches for phenotyping patients and identify ing those who are most likely to respond to treatment. These efforts -which include ACTTION (www.acttion.org), EuroPain (www.imieuropain.org) and the German Research Network on Neuropathic Pain (www.neuro.med.tumuenchen.de/dfns/) -are providing an evidence base for the design of future neuropathic pain clinical trials and for the develop ment of mechanism based approaches to personalized neuropathic pain treatment.
Personalized pain medicine
Personalized medical care refers to the principle that patients can be stratified such that each patient receives the most effective and tolerable treatment for their individ ual needs. Patients can be stratified on several levels: clinical phenotype, detailed sensory profiling, genetics and potentially (in the future) using cellular models to facilitate treatment choice. Close consultation with the patient is required and this involves complex discussions around the uncertainties of genetic risk and the balance between efficacy and tolerability of potential treatments. Human genetics studies have demonstrated that Na v 1.7 is a crucial pain target 189 , and therapeutics aimed at targeting Na v 1.7 provide an example of a situ ation in which testing for specific genetic mutations can inform patient care. Lossoffunction mutations lead to congenital insensitivity to pain and gainoffunction mutations cause rare inherited pain disorders, includ ing inherited erythromelalgia 31 , paroxysmal extreme pain disorder 32 and idiopathic smallfibre neuropathy (which involves pain and smallfibre degeneration in the extremities) 33 . Genetic information can, therefore, inform diag nostics; however, the interpretation of genetic results is complex and should be accompanied by functional analysis of mutant ion channels wherever possible 190 . For instance, in the context of smallfibre neuropathy, muta tions might not be fully penetrant. Finding a mutation in SCN9A may have immediate implications for treatment in choosing a drug with activity against voltagegated sodium channels (not normally firstline agents in the treatment of neuropathic pain), such as mexiletine, which is not recommended in the treatment of neuropathic pain but is used in inherited erythromelalgia, in which mexiletine has proven efficacy in normalizing abnor mal channel properties in vitro 191 and clinical efficacy in individual cases. A further step has been taken in using structural modelling of Na v 1.7 to predict what treatment a speci fic mutation will respond to 192 ; the modelling results were used to predict the efficacy of carbamazepine (a voltage gated sodium channel blocker) in inherited erythromelalgia associated with the SCN9A S241T muta tion 193 . Furthermore, the generation of nociceptors in vitro using patientderived induced pluripotent stem cells is now possible. In rare Mendelian pain disorders (such as inherited erythromelalgia), these nociceptors have been shown to be hyperexcitable 194 . Treatments tar geting Na v 1.7 can be screened in such cellular models and related to clinical efficacy as proof of concept before their use in patients (these nociceptors have been shown to be hyperexcitable in inherited erythromelalgia 194 ). Genetic stratification is more challenging in common acquired neuropathic pain states, such as painful dia betic neuropathy, because such conditions are polygenic and subject to considerable environmental interaction. Thus, the relevance of an individual target such as Na v 1.7 in these conditions is less clear. Despite these limitations, the prospect of personalized medicine is a step forward towards promising pain management strategies. The prevalence, severity, and impact of painful diabetic peripheral neuropathy in type 2 diabetes.
